The REWIND trial
Update 06-10-2019 | Dulaglutide cardioprotective in relatively low-risk REWIND population
Presenters: Gilles R. Dagenais, MD; Rafael Diaz, MD; Matthew C. Riddle, MD; Hertzel C. Gerstein, MD, MSc, FRCPC; Jeffrey L. Probstfield, MD; Lars Rydén, MD, PhD; Sophia Zoungas, MBBS (Hons), PhD, FRACP.
Sunday 9 June: 16:30–18:30
REWIND (Researching CV Events with a Weekly INcretin in Diabetes) is not the first trial assessing the cardiovascular safety of a weekly injectable glugacon-like peptide-1 (GLP-1) receptor agonist, but it is the first to focus on relatively low-risk patients; only a third of participants had established cardiovascular disease at baseline.
The press-released top-line findings show a significant reduction in cardiovascular risk with dulaglutide versus placebo. This implies a role for GLP-1 receptor agonists for the primary prevention of cardiovascular disease in people with type 2 diabetes, pending confirmation of the findings at ADA and presentation of outcomes in people with/without established atherosclerotic disease.
- External link | Published design and baseline characteristics of REWIND
- Quick guide | Round-up of the GLP-1 receptor agonist CV outcome trials
- Clinical trial commentary | WATCH: John Wilding discusses the unexpected HARMONY results